<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Jpn J Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">Jpn. J. Cancer Res</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006a</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Japanese Journal of Cancer Research : Gann</journal-title></journal-title-group><issn pub-type="ppub">0910-5050</issn><issn pub-type="epub">1876-4673</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">2126002</article-id><article-id pub-id-type="pmc">5918012</article-id><article-id pub-id-type="doi">10.1111/j.1349-7006.1990.tb02697.x</article-id><article-id pub-id-type="publisher-id">CAE1320</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Multi&#x02010;drug Combination Therapy with Vincristine&#x02010;Melphalan&#x02010;Cyclophosphamide&#x02010;Prednisolone Was More Effective than Cyclophosphamide&#x02010;Prednisolone in Stage III Myeloma</article-title></title-group><contrib-group><contrib id="cr1" contrib-type="author"><name><surname>Shimizu</surname><given-names>Kazuyuki</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr2" contrib-type="author"><name><surname>Kamiya</surname><given-names>Osamu</given-names></name><xref ref-type="aff" rid="a2"><sup>2</sup></xref></contrib><contrib id="cr3" contrib-type="author"><name><surname>Hamajima</surname><given-names>Nobuyuki</given-names></name><xref ref-type="aff" rid="a3"><sup>3</sup></xref></contrib><contrib id="cr4" contrib-type="author"><name><surname>Mizuno</surname><given-names>Harumitsu</given-names></name><xref ref-type="aff" rid="a4"><sup>4</sup></xref></contrib><contrib id="cr5" contrib-type="author"><name><surname>Kobayashi</surname><given-names>Masahide</given-names></name><xref ref-type="aff" rid="a5"><sup>5</sup></xref></contrib><contrib id="cr6" contrib-type="author"><name><surname>Hirabayashi</surname><given-names>Noriyuki</given-names></name><xref ref-type="aff" rid="a6"><sup>6</sup></xref></contrib><contrib id="cr7" contrib-type="author"><name><surname>Takeyama</surname><given-names>Hideo</given-names></name><xref ref-type="aff" rid="a7"><sup>7</sup></xref></contrib><contrib id="cr8" contrib-type="author"><name><surname>Kato</surname><given-names>Ryoichi</given-names></name><xref ref-type="aff" rid="a8"><sup>8</sup></xref></contrib><contrib id="cr9" contrib-type="author"><name><surname>Kawashima</surname><given-names>Kohei</given-names></name><xref ref-type="aff" rid="a9"><sup>9</sup></xref></contrib><contrib id="cr10" contrib-type="author"><name><surname>Nitta</surname><given-names>Masakazu</given-names></name><xref ref-type="aff" rid="a10"><sup>10</sup></xref></contrib><contrib id="cr11" contrib-type="author"><name><surname>Hotta</surname><given-names>Tomomitsu</given-names></name><xref ref-type="aff" rid="a3"><sup>3</sup></xref></contrib><contrib id="cr12" contrib-type="author"><name><surname>Utsumi</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="a11"><sup>11</sup></xref></contrib><contrib id="cr13" contrib-type="author"><name><surname>Nagura</surname><given-names>Eiichi</given-names></name><xref ref-type="aff" rid="a12"><sup>12</sup></xref></contrib></contrib-group><aff id="a1"><label><sup>1</sup></label>Fujita Health University School of Medicine, Toyoake 470&#x02013;11</aff><aff id="a2"><label><sup>2</sup></label>Anjo Kosei Hospital, Anjo 446</aff><aff id="a3"><label><sup>3</sup></label>Nagoya University School of Medicine, Nagoya 466</aff><aff id="a4"><label><sup>4</sup></label>Chukyo Hospital, Nagoya 457</aff><aff id="a5"><label><sup>5</sup></label>Seibu Medical Center, Hamamatsu 432</aff><aff id="a6"><label><sup>6</sup></label>Second Red Cross Hospital, Nagoya 466</aff><aff id="a7"><label><sup>7</sup></label>Ekisaikai Hospital, Nagoya 454</aff><aff id="a8"><label><sup>8</sup></label>Aichi Medical College, Nagakute 480&#x02013;11</aff><aff id="a9"><label><sup>9</sup></label>Yokkaichi Municipal Hospital, Yokkaichi 510</aff><aff id="a10"><label><sup>10</sup></label>Nagoya City University School of Medicine, Nagoya 467</aff><aff id="a11"><label><sup>11</sup></label>Tajimi Prefectural Hospital, Tajimi 507</aff><aff id="a12"><label><sup>12</sup></label>National Chubu Hospital, Obu 474</aff><pub-date pub-type="ppub"><month>12</month><year>1990</year></pub-date><volume>81</volume><issue>12</issue><issue-id pub-id-type="doi">10.1111/cas.1990.81.issue-12</issue-id><fpage>1320</fpage><lpage>1327</lpage><history>
(Received June 20, 1990/Accepted September 28, 1990)</history><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAS-81-1320.pdf"/><abstract><p>A cooperative randomized clinical trial to compare the effectiveness of multi&#x02010;drug combination chemotherapy (VMCP, vincristine&#x02010;melphalan&#x02010;cyclophosphamide&#x02010;prednisolone) with CP (cyclophosphamide&#x02010;prednisolone) for the treatment of multiple myeloma was performed. When the whole group of patients was evaluated, the choice of chemotherapy (VMCP or CP) was not a significant prognostic factor associated with response or survival by uni&#x02010; or multivariate analysis, and the difference between the survival curves of the treatment groups was only marginally significant. However, when the analysis was confined to stage III patients, the choice of chemotherapy became a significant prognostic factor associated with both response rate and survival, and the statistical difference between survival curves was significant. Taking the disease characteristics of multiple myeloma into consideration, the better result obtained with multi&#x02010;drug combination chemotherapy in the treatment of stage III patients is consistent with other studies supporting the superiority of multi&#x02010;drug combination chemotherapy for patients with overt systemic disease.</p></abstract><kwd-group><kwd id="k1">Multiple myeloma</kwd><kwd id="k2">Multi&#x02010;drug combination chemotherapy</kwd><kwd id="k3">Standard chemotherapy</kwd><kwd id="k4">Multivariate analyses</kwd><kwd id="k5">Prognostic factors</kwd></kwd-group><counts><ref-count count="29"/><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 1990</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="n-fnt-1"><p>Communications should be directed to: Kazuyuki Shimizu, M.D.: Department of Medicine, Fujita Health University School of Medicine, Kutsukake&#x02010;cho, Toyoake, Aichi 470&#x02013;11.</p></fn></fn-group></notes></front><back><ref-list id="ss1"><title>REFERENCES</title><ref id="b1"><label>1</label><mixed-citation publication-type="journal" id="cit1">
)
<string-name><surname>Alexanian</surname>
,
<given-names>R.</given-names></string-name>
,
<string-name><surname>Bonnet</surname>
,
<given-names>H.</given-names></string-name>
,
<string-name><surname>Gehan</surname>
,
<given-names>E.</given-names></string-name>
,
<string-name><surname>Haut</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Hewlett</surname>
,
<given-names>J.</given-names></string-name>
,
<string-name><surname>Lane</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Monto</surname>
,
<given-names>R.</given-names></string-name>
and
<string-name><surname>Wilson</surname>
,
<given-names>H.</given-names></string-name><article-title>Combination chemotherapy for multiple myeloma</article-title>
.
<source>Cancer</source>
,
<volume>30</volume>
,
<fpage>382</fpage>
&#x02013;
<lpage>389</lpage>
(
<year>1972</year>
).
<pub-id pub-id-type="pmid">5051662</pub-id></mixed-citation></ref><ref id="b2"><label>2</label><mixed-citation publication-type="journal" id="cit2">
)
<string-name><surname>Harley</surname>
,
<given-names>J. B.</given-names></string-name>
,
<string-name><surname>Pajak</surname>
,
<given-names>T. F.</given-names></string-name>
,
<string-name><surname>McIntyre</surname>
,
<given-names>O. R.</given-names></string-name>
,
<string-name><surname>Kochwa</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Cooper</surname>
,
<given-names>M. R.</given-names></string-name>
,
<string-name><surname>Coleman</surname>
,
<given-names>M.</given-names></string-name>
and
<string-name><surname>Cuttner</surname>
,
<given-names>J.</given-names></string-name><article-title>Improved survival of increased risk myeloma patients on combined triple alkylating agent therapy: a study of the CALGB</article-title>
.
<source>Blood</source>
,
<volume>54</volume>
,
<fpage>13</fpage>
&#x02013;
<lpage>22</lpage>
(
<year>1979</year>
).
<pub-id pub-id-type="pmid">444661</pub-id></mixed-citation></ref><ref id="b3"><label>3</label><mixed-citation publication-type="journal" id="cit3">
)
<string-name><surname>Bergsagel</surname>
,
<given-names>D. E.</given-names></string-name>
,
<string-name><surname>Bailey</surname>
,
<given-names>A. J.</given-names></string-name>
,
<string-name><surname>Langley</surname>
,
<given-names>G. R.</given-names></string-name>
,
<string-name><surname>MacDonald</surname>
,
<given-names>R. N.</given-names></string-name>
,
<string-name><surname>White</surname>
,
<given-names>D. F.</given-names></string-name>
and
<string-name><surname>Miller</surname>
,
<given-names>A. B.</given-names></string-name><article-title>The chemotherapy of plasma cell myeloma and the incidence of acute leukemia</article-title>
.
<source>N. Engl. J. Med.</source>
,
<volume>302</volume>
,
<fpage>743</fpage>
&#x02013;
<lpage>748</lpage>
(
<year>1979</year>
).
</mixed-citation></ref><ref id="b4"><label>4</label><mixed-citation publication-type="journal" id="cit4">
)
<string-name><surname>Cavagnaro</surname>
,
<given-names>F.</given-names></string-name>
,
<string-name><surname>Lein</surname>
,
<given-names>J. M.</given-names></string-name>
,
<string-name><surname>Pavlovsky</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Becherin</surname>
,
<given-names>J. O.</given-names></string-name>
,
<string-name><surname>Pileggi</surname>
,
<given-names>J. E.</given-names></string-name>
,
<string-name><surname>Quiroga Micheo</surname>
,
<given-names>E.</given-names></string-name>
,
<string-name><surname>Jait</surname>
,
<given-names>C.</given-names></string-name>
,
<string-name><surname>Musso</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Suarez</surname>
,
<given-names>A.</given-names></string-name>
and
<string-name><surname>Pizzolato</surname>
,
<given-names>M.</given-names></string-name><article-title>Comparison of two combination chemotherapy regimens for multiple myeloma: methyl&#x02010;CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone</article-title>
.
<source>Cancer Treat. Rep.</source>
,
<volume>64</volume>
,
<fpage>73</fpage>
&#x02013;
<lpage>79</lpage>
(
<year>1980</year>
).
<pub-id pub-id-type="pmid">6991106</pub-id></mixed-citation></ref><ref id="b5"><label>5</label><mixed-citation publication-type="journal" id="cit5">
)
<string-name><surname>Abramson</surname>
,
<given-names>N.</given-names></string-name>
,
<string-name><surname>Lurie</surname>
,
<given-names>P.</given-names></string-name>
,
<string-name><surname>Mietlowski</surname>
,
<given-names>W.</given-names></string-name>
,
<string-name><surname>Schilling</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Bonnet</surname>
,
<given-names>J. M.</given-names></string-name>
and
<string-name><surname>Horton</surname>
,
<given-names>H. J.</given-names></string-name><article-title>Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma</article-title>
.
<source>Cancer Treat. Rep.</source>
,
<volume>66</volume>
,
<fpage>1273</fpage>
&#x02013;
<lpage>1277</lpage>
(
<year>1982</year>
).
<pub-id pub-id-type="pmid">7044535</pub-id></mixed-citation></ref><ref id="b6"><label>6</label><mixed-citation publication-type="journal" id="cit6">
)
<string-name><surname>Salmon</surname>
,
<given-names>S. E.</given-names></string-name>
,
<string-name><surname>Haut</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Bonnet</surname>
,
<given-names>J. D.</given-names></string-name>
,
<string-name><surname>Amare</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Weick</surname>
,
<given-names>J. K.</given-names></string-name>
,
<string-name><surname>Durie</surname>
,
<given-names>B. G. M.</given-names></string-name>
and
<string-name><surname>Dixon</surname>
,
<given-names>D. O.</given-names></string-name><article-title>Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study</article-title>
.
<source>J. Clin. Oncol.</source>
,
<volume>1</volume>
,
<fpage>453</fpage>
&#x02013;
<lpage>461</lpage>
(
<year>1983</year>
).
<pub-id pub-id-type="pmid">6366141</pub-id></mixed-citation></ref><ref id="b7"><label>7</label><mixed-citation publication-type="journal" id="cit7">
)
<string-name><surname>Alexanian</surname>
,
<given-names>R.</given-names></string-name>
and
<string-name><surname>Dreicer</surname>
,
<given-names>R.</given-names></string-name><article-title>Chemotherapy for multiple myeloma</article-title>
.
<source>Cancer</source>
,
<volume>53</volume>
,
<fpage>583</fpage>
&#x02013;
<lpage>588</lpage>
(
<year>1984</year>
).
<pub-id pub-id-type="pmid">6362819</pub-id></mixed-citation></ref><ref id="b8"><label>8</label><mixed-citation publication-type="journal" id="cit8">
)
<string-name><surname>Oken</surname>
,
<given-names>M. M.</given-names></string-name>
,
<string-name><surname>Tsiatis</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Abramson</surname>
,
<given-names>N.</given-names></string-name>
and
<string-name><surname>Glick</surname>
,
<given-names>J.</given-names></string-name><article-title>Comparison of standard (MP) with intensive (VBMCP) therapy for the treatment of multiple myeloma</article-title>
.
<source>Proc. Am. Soc. Clin. Oncol.</source>
,
<volume>3</volume>
,
<fpage>270</fpage>
(
<year>1984</year>
).
</mixed-citation></ref><ref id="b9"><label>9</label><mixed-citation publication-type="journal" id="cit9">
)
<string-name><surname>Pavlovsky</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Saslavsky</surname>
,
<given-names>J.</given-names></string-name>
,
<string-name><surname>Tezanos Pinto</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Palmer</surname>
,
<given-names>L.</given-names></string-name>
,
<string-name><surname>Curuchet</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Lein</surname>
,
<given-names>J. M.</given-names></string-name>
,
<string-name><surname>Garay</surname>
,
<given-names>G.</given-names></string-name>
,
<string-name><surname>Dragoski</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Quiroga Micheo</surname>
,
<given-names>E.</given-names></string-name>
,
<string-name><surname>Huberman</surname>
,
<given-names>A. B.</given-names></string-name>
and
<string-name><surname>Pizzolato</surname>
,
<given-names>M.</given-names></string-name><article-title>A randomized trial of melphalan, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma</article-title>
.
<source>J. Clin. Oncol.</source>
,
<volume>2</volume>
,
<fpage>836</fpage>
&#x02013;
<lpage>840</lpage>
(
<year>1984</year>
).
<pub-id pub-id-type="pmid">6376722</pub-id></mixed-citation></ref><ref id="b10"><label>10</label><mixed-citation publication-type="journal" id="cit10">
)
<string-name><surname>Bergsagel</surname>
,
<given-names>D. E.</given-names></string-name><article-title>Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma</article-title>
?
<source>Eur. J. Cancer Clin. Oncol.</source>
,
<volume>24</volume>
,
<fpage>1061</fpage>
&#x02013;
<lpage>1067</lpage>
(
<year>1988</year>
).
<pub-id pub-id-type="pmid">3044800</pub-id></mixed-citation></ref><ref id="b11"><label>11</label><mixed-citation publication-type="journal" id="cit11">
)
<collab collab-type="authors">Report of the Medical Research Council's Working Party for Therapeutic Trials in Leukemia</collab>
.
<article-title>Myelomatosis: comparison of melphalan and cyclophosphamide</article-title>
.
<source>Br. Med. J.</source>
,
<volume>1</volume>
,
<fpage>640</fpage>
&#x02013;
<lpage>641</lpage>
(
<year>1971</year>
).
<pub-id pub-id-type="pmid">4926948</pub-id></mixed-citation></ref><ref id="b12"><label>12</label><mixed-citation publication-type="journal" id="cit12">
)
<string-name><surname>Rivers</surname>
,
<given-names>S. L.</given-names></string-name>
and
<string-name><surname>Patno</surname>
,
<given-names>M. E.</given-names></string-name><article-title>Cyclophosphamide vs. melphalan in treatment of plasma cell myeloma</article-title>
.
<source>J. Am. Med. Assoc.</source>
,
<volume>207</volume>
,
<fpage>1328</fpage>
&#x02013;
<lpage>1334</lpage>
(
<year>1969</year>
).
</mixed-citation></ref><ref id="b13"><label>13</label><mixed-citation publication-type="journal" id="cit13">
)
<string-name><surname>Durie</surname>
,
<given-names>B. G. M.</given-names></string-name><article-title>Staging and kinetics of multiple myeloma</article-title>
.
<source>Semin. Oncol.</source>
,
<volume>13</volume>
,
<fpage>300</fpage>
&#x02013;
<lpage>309</lpage>
(
<year>1986</year>
).
<pub-id pub-id-type="pmid">3532329</pub-id></mixed-citation></ref><ref id="b14"><label>14</label><mixed-citation publication-type="journal" id="cit14">
)
<collab collab-type="authors">Chronic Leukemia&#x02010;Myeloma Task Force, National Cancer Institute</collab>
.
<article-title>Proposed guidelines for protocol studies. II. Plasma cell myeloma</article-title>
.
<source>Cancer Treat. Rep.</source>
,
<volume>4</volume>
,
<fpage>145</fpage>
&#x02013;
<lpage>158</lpage>
(
<year>1973</year>
).
</mixed-citation></ref><ref id="b15"><label>15</label><mixed-citation publication-type="journal" id="cit15">
)
<string-name><surname>Durie</surname>
,
<given-names>B. G. M.</given-names></string-name>
and
<string-name><surname>Salmon</surname>
,
<given-names>S. E.</given-names></string-name><article-title>A clinical staging system for multiple myeloma</article-title>
.
<source>Cancer</source>
,
<volume>36</volume>
,
<fpage>842</fpage>
&#x02013;
<lpage>854</lpage>
(
<year>1975</year>
).
<pub-id pub-id-type="pmid">1182674</pub-id></mixed-citation></ref><ref id="b16"><label>16</label><mixed-citation publication-type="book" id="cit16">
)
<string-name><surname>Cox</surname>
,
<given-names>D. R.</given-names></string-name>
&#x0201c;
<source>The Analysis of Binary Data</source>
&#x0201d; (
<year>1970</year>
).
<publisher-name>Chapman and Hill</publisher-name>
,
New York
.
</mixed-citation></ref><ref id="b17"><label>17</label><mixed-citation publication-type="book" id="cit17">
)
<string-name><surname>Harrell</surname>
,
<given-names>F. E.</given-names></string-name><chapter-title>The LOGIST procedure</chapter-title>
.
<italic>In</italic>
&#x0201c;
<source>SUGI Supplemental Library User's Guide</source>
,&#x0201d;
pp.
<fpage>181</fpage>
&#x02013;
<lpage>201</lpage>
(
<year>1983</year>
).
<publisher-name>SAS Institute</publisher-name>
,
Cary
,
N.C
.
</mixed-citation></ref><ref id="b18"><label>18</label><mixed-citation publication-type="book" id="cit18">
) &#x0201c;
<source>SAS User's Guide. Statistics</source>
&#x0201d; (
<year>1982</year>
).
<publisher-name>SAS Institute</publisher-name>
,
Cary
,
N.C
.
</mixed-citation></ref><ref id="b19"><label>19</label><mixed-citation publication-type="journal" id="cit19">
)
<string-name><surname>Kaplan</surname>
,
<given-names>E.</given-names></string-name>
and
<string-name><surname>Meier</surname>
,
<given-names>P.</given-names></string-name><article-title>Nonparametric estimation from incomplete observation</article-title>
.
<source>J. Am. Stat. Assoc.</source>
,
<volume>53</volume>
,
<fpage>457</fpage>
&#x02013;
<lpage>481</lpage>
(
<year>1958</year>
).
</mixed-citation></ref><ref id="b20"><label>20</label><mixed-citation publication-type="journal" id="cit20">
)
<string-name><surname>Gehan</surname>
,
<given-names>E.</given-names></string-name><article-title>A generalized Wilcoxon test for comparing arbitrarily singly&#x02010;censored samples</article-title>
.
<source>Biometrika</source>
,
<volume>52</volume>
,
<fpage>203</fpage>
&#x02013;
<lpage>223</lpage>
(
<year>1965</year>
).
<pub-id pub-id-type="pmid">14341275</pub-id></mixed-citation></ref><ref id="b21"><label>21</label><mixed-citation publication-type="journal" id="cit21">
)
<string-name><surname>Mantel</surname>
,
<given-names>N.</given-names></string-name><article-title>Evaluation of survival data and two new rank order statistics arising in its consideration</article-title>
.
<source>Cancer Chemother. Rep.</source>
,
<volume>50</volume>
,
<fpage>165</fpage>
&#x02013;
<lpage>170</lpage>
(
<year>1966</year>
).
</mixed-citation></ref><ref id="b22"><label>22</label><mixed-citation publication-type="journal" id="cit22">
)
<string-name><surname>Cox</surname>
,
<given-names>D. R.</given-names></string-name><article-title>Regression models and life tables</article-title>
.
<source>J. R. Stat. Soc. Ser. B</source>
,
<volume>34</volume>
,
<fpage>87</fpage>
&#x02013;
<lpage>220</lpage>
(
<year>1972</year>
).
</mixed-citation></ref><ref id="b23"><label>23</label><mixed-citation publication-type="book" id="cit23">
)
<string-name><surname>Harrell</surname>
,
<given-names>F. E.</given-names></string-name><chapter-title>The PHGLM procedure</chapter-title>
.
<italic>In</italic>
&#x0201c;
<source>SUGI Supplemental Library User's Guide</source>
,&#x0201d;
pp.
<fpage>267</fpage>
&#x02013;
<lpage>294</lpage>
(
<year>1983</year>
).
<publisher-name>SAS Institute</publisher-name>
,
Cary
,
N.C
.
</mixed-citation></ref><ref id="b24"><label>24</label><mixed-citation publication-type="journal" id="cit24">
)
<string-name><surname>Durie</surname>
,
<given-names>B. G. M.</given-names></string-name>
,
<string-name><surname>Dixon</surname>
,
<given-names>D. O.</given-names></string-name>
,
<string-name><surname>Carter</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Rivkin</surname>
,
<given-names>S. S.</given-names></string-name>
,
<string-name><surname>Bonnet</surname>
,
<given-names>J.</given-names></string-name>
,
<string-name><surname>Salmon</surname>
,
<given-names>S. E.</given-names></string-name>
,
<string-name><surname>Dabich</surname>
,
<given-names>L.</given-names></string-name>
,
<string-name><surname>Files</surname>
,
<given-names>J. C.</given-names></string-name>
and
<string-name><surname>Costanzi</surname>
,
<given-names>J. J.</given-names></string-name><article-title>Improved survival duration with combination chemotherapy induction for multiple myeloma: A Southwest Oncology Group Study</article-title>
.
<source>J. Clin. Oncol.</source>
,
<volume>4</volume>
,
<fpage>1227</fpage>
&#x02013;
<lpage>1237</lpage>
(
<year>1986</year>
).
<pub-id pub-id-type="pmid">3525768</pub-id></mixed-citation></ref><ref id="b25"><label>25</label><mixed-citation publication-type="journal" id="cit25">
)
<string-name><surname>Mizuno</surname>
,
<given-names>H.</given-names></string-name>
,
<string-name><surname>Ninomiya</surname>
,
<given-names>N.</given-names></string-name>
,
<string-name><surname>Ohta</surname>
,
<given-names>H.</given-names></string-name>
,
<string-name><surname>Tokoro</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Ohnishi</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Ikeda</surname>
,
<given-names>Y.</given-names></string-name>
and
<string-name><surname>Yasuma</surname>
,
<given-names>A.</given-names></string-name><article-title>Treatment of multiple myeloma (IV). Therapy with high&#x02010;dose intermittent administration of cyclophosphamide and prednisolone &#x02014; follow&#x02010;up study of 10 years period</article-title>
.
<source>Jpn. J. Cancer Chemother.</source>
,
<volume>10</volume>
,
<fpage>2286</fpage>
&#x02013;
<lpage>2291</lpage>
(
<year>1983</year>
).
</mixed-citation></ref><ref id="b26"><label>26</label><mixed-citation publication-type="journal" id="cit26">
)
<string-name><surname>Paredes</surname>
,
<given-names>J. M.</given-names></string-name>
and
<string-name><surname>Mitchell</surname>
,
<given-names>B. S.</given-names></string-name><article-title>Multiple myeloma. Current concepts in diagnosis and management</article-title>
.
<source>Med. Clin. North Am.</source>
,
<volume>64</volume>
,
<fpage>729</fpage>
&#x02013;
<lpage>742</lpage>
(
<year>1980</year>
).
<pub-id pub-id-type="pmid">6995732</pub-id></mixed-citation></ref><ref id="b27"><label>27</label><mixed-citation publication-type="journal" id="cit27">
)
<string-name><surname>Kyle</surname>
,
<given-names>R. A.</given-names></string-name>
and
<string-name><surname>Greipp</surname>
,
<given-names>P. P.</given-names></string-name><article-title>Smoldering multiple myeloma</article-title>
.
<source>N. Engl. J. Med.</source>
,
<volume>302</volume>
,
<fpage>1347</fpage>
&#x02013;
<lpage>1349</lpage>
(
<year>1980</year>
).
<pub-id pub-id-type="pmid">7374679</pub-id></mixed-citation></ref><ref id="b28"><label>28</label><mixed-citation publication-type="journal" id="cit28">
)
<string-name><surname>Alexanian</surname>
,
<given-names>R.</given-names></string-name>
,
<string-name><surname>Barlogie</surname>
,
<given-names>B.</given-names></string-name>
and
<string-name><surname>Dixon</surname>
,
<given-names>D.</given-names></string-name><article-title>Prognosis of asymptomatic multiple myeloma</article-title>
.
<source>Arch. Intern. Med.</source>
,
<volume>148</volume>
,
<fpage>1963</fpage>
&#x02013;
<lpage>1965</lpage>
(
<year>1988</year>
).
<pub-id pub-id-type="pmid">2458080</pub-id></mixed-citation></ref><ref id="b29"><label>29</label><mixed-citation publication-type="journal" id="cit29">
)
<string-name><surname>Bergsagel</surname>
,
<given-names>D. E.</given-names></string-name><article-title>Controversies in the treatment of plasma cell myeloma</article-title>
.
<source>Postgrad. Med. J.</source>
,
<volume>61</volume>
,
<fpage>109</fpage>
&#x02013;
<lpage>116</lpage>
(
<year>1985</year>
).
<pub-id pub-id-type="pmid">3983038</pub-id></mixed-citation></ref></ref-list></back></article>